Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
Cleveland Clinic Journal of Medicine · 2024
DOI: 10.3949/ccjm.91c.02001 ↗Kurz gefasst
Leserbrief in der Zeitschrift Cleveland Clinic Journal of Medicine, 2024. Verfasst von Taher Modarressi. Beteiligte Einrichtung: Princeton Cardiometabolic Health, Pennington, NJ. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
To the Editor: The article by Sekerak and colleagues[1][1] is an excellent highlight of the sodium-glucose cotransporter 2 (SGLT-2) inhibitor family’s pluripotent cardiorenal impacts. I offer several suggestions to optimize the utilization of this therapeutic class. First, regarding dosing, while
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Princeton Cardiometabolic Health, Pennington, NJ.
Zitieren
APA
Modarressi, T. (2024). Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?. Cleveland Clinic Journal of Medicine. https://doi.org/10.3949/ccjm.91c.02001
Vancouver
Modarressi T. Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?. Cleveland Clinic Journal of Medicine. 2024. doi:10.3949/ccjm.91c.02001
BibTeX
@article{Modarressi2024,
author = {Modarressi, Taher},
title = {Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?},
journal = {Cleveland Clinic Journal of Medicine},
year = {2024},
doi = {10.3949/ccjm.91c.02001}
}
EUVIMED